Zobrazeno 1 - 10
of 51
pro vyhledávání: '"A.B.M. Foot"'
Publikováno v:
European Journal of Cancer. 46:1588-1595
Results are presented of the SIOP study MMT-98 for paediatric metastatic rhabdomyosarcoma (RMS), which evaluated intensive chemotherapy followed by low intensity 'maintenance' chemotherapy in standard risk patients (SRG). For poor risk patients (PRG)
Autor:
Andrew D.J. Pearson, B. De Bernardi, Genevieve Laureys, Jean Michon, Ruth Ladenstein, A F de Lacerda, Paolo Bruzzi, Maja Beck-Popovic, Hervé Rubie, Victoria Castel, Véronique Mosseri, Peter F. Ambros, A.B.M. Foot, Massimo Conte, J. de Kraker, Y. De Rycke
Publikováno v:
British Journal of Cancer
British Journal of Cancer, vol. 99, no. 7, pp. 1027-1033
British journal of cancer, 99(7), 1027-1033. Nature Publishing Group
British Journal of Cancer, vol. 99, no. 7, pp. 1027-1033
British journal of cancer, 99(7), 1027-1033. Nature Publishing Group
Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1–2 patients, 411 had normal MYCN and 1
Autor:
Julia C. Chisholm, Meriel Jenney, Kieran McHugh, David Machin, Heather P. McDowell, A.B.M. Foot, C. Ellershaw
Publikováno v:
European Journal of Cancer. 43:2537-2544
Aim The activity of carboplatin was evaluated in a phase II window study in previously untreated children with metastatic soft tissue sarcoma. Methods Children with poor-risk metastatic disease (over 10 years and/or with bone/bone marrow involvement)
Autor:
D.G. Pearson, Caroline Ellershaw, Andrew D.J. Pearson, Julie Errington, Gareth J. Veal, Geoff Nowell, A.B.M. Foot, B Pizer, Michael J. Tilby, Heather P. McDowell, Alan V. Boddy
Publikováno v:
British Journal of Cancer
A pharmacokinetic–pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic monitoring following high-dose carboplatin treatment in children. High-dose carboplatin was administered over 3 or 5 days
Autor:
Gareth J. Veal, Alan V. Boddy, A.B.M. Foot, Michael Cole, Julie Errington, Andrew D.J. Pearson, Gavin Whyman
Publikováno v:
British Journal of Cancer
The administration of 13-cis-retinoic acid (13-cisRA), following myeloablative therapy improves 3-year event-free survival rates in children with high-risk neuroblastoma. This study aimed to determine the degree of inter-patient pharmacokinetic varia
Publikováno v:
Medical and Pediatric Oncology. 36:235-238
Background and Procedure Most deaths from neuroblastoma occur within 2 years of diagnosis but there have been several anecdotal reports of relapse and death after much longer periods of follow up. In order to investigate and quantify the risk of late
Publikováno v:
Medical and Pediatric Oncology. 32:170-176
Background. A prospective follow-up was undertaken to document longitudinal changes in lung function in children with neuroblastoma treated with the Lyon-Marseille-Curie-East of France Group protocol, consisting of high-dose chemotherapy schedules in
Autor:
Charles A. Stiller, A.B.M. Foot, K. Pritchard Jones, Anna Kelsey, Gordan M. Vujanic, Richard Grundy, Bernadette Brennan
Publikováno v:
European journal of cancer (Oxford, England : 1990). 40(4)
Rhabdoid tumours are rare, highly aggressive and frequently lethal tumours of childhood. Renal rhabdoid tumour was first recognised as a separate pathological entity in the early 1980s [1]. Atypical teratoid/rhabdoid tumour (AT/RT) of the central ner
Autor:
Nicholas J. Goulden, David Carrington, David I. Marks, Colin G. Steward, J Cornish, A.B.M. Foot, A Oakhill, Derwood Pamphilon, Milind D. Ronghe
Publikováno v:
British journal of haematology. 118(4)
Summary. The impact of transfusion of leucodepleted platelet concentrates (PCs) on cytomegalovirus (CMV) disease was assessed in 215 allogeneic (145 unrelated and 70 related donor) transplants over 3 years. In 43%, both donor and patient were CMV ser
Publikováno v:
European journal of cancer (Oxford, England : 1990). 36(7)
In 1982 the European Neuroblastoma Study Group (ENSG) established a prospective registry for patients with newly diagnosed neuroblastoma ('The ENSG Survey'). Clinical information was collected primarily to: (a) establish an ENSG database; and (b) inv